ClinicaliQ Trial Snapshot
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) — Recruiting • Phase III • Oncology •….
- What is being tested: Elranatamab, a bispecific antibody targeting BCMA and CD3, is being evaluated against standard treatments in relapsed/refractory multiple myeloma (RRMM) patients who have previously failed anti-CD38 antibodies and lenalidomide.
- Patient eligibility overview: Adults aged 18+ with multiple myeloma that has progressed after prior treatment with anti-CD38 monoclonal antibodies (e.g. daratumumab) and lenalidomide are eligible for enrolment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study…
Eligibility Snapshot
- : * Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide. * Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria. * Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (1.65). * Have clinical laboratory values within the specified range. * ECOG (Eastern Cooperative Oncology Group) performance status ≤2. * Not pregnant or breastfeeding and willing to use contraception.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.